SS-31 (elamipretide): selected references HeartPep literature library, reviewed 2026-11-09 https://heartpep.com/us/research/library/ss-31 1. Nickel K, Zhu L, Mangalindan R, et al. (2022). Long-term treatment with Elamipretide enhances healthy aging phenotypes in mice Aging Pathobiology and Therapeutics. DOI: https://doi.org/10.31491/apt.2022.09.089 PMID: 36250163 Source: https://pubmed.ncbi.nlm.nih.gov/36250163/ Verification: Abstract / bibliographic record. 2. Karaa A, Bertini E, Carelli V, et al.; MMPOWER-3 Trial Investigators (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial Neurology. DOI: https://doi.org/10.1212/WNL.0000000000207402 PMID: 37268435 Source: https://pubmed.ncbi.nlm.nih.gov/37268435/ Verification: Full text. 3. Thompson WR, Hornby B, Manuel R, et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism Genetics in Medicine. DOI: https://doi.org/10.1038/s41436-020-01006-8 PMID: 33077895 Source: https://pubmed.ncbi.nlm.nih.gov/33077895/ Verification: Full text. 4. Thompson WR, Manuel R, Abbruscato A, et al. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER Genetics in Medicine. DOI: https://doi.org/10.1016/j.gim.2024.101138 PMID: 38602181 Source: https://pubmed.ncbi.nlm.nih.gov/38602181/ Verification: Abstract / bibliographic record. These are selected background references, not evidence that a HeartPep product or batch matches a studied preparation. Cite and assess the original papers.